Show simple item record

AuthorAbu-Raddad, Laith J
AuthorChemaitelly, Hiam
AuthorAyoub, Houssein H
AuthorYassine, Hadi M
AuthorBenslimane, Fatiha M
AuthorAl Khatib, Hebah A
AuthorTang, Patrick
AuthorHasan, Mohammad R
AuthorCoyle, Peter
AuthorAlMukdad, Sawsan
AuthorAl Kanaani, Zaina
AuthorAl Kuwari, Einas
AuthorJeremijenko, Andrew
AuthorKaleeckal, Anvar Hassan
AuthorLatif, Ali Nizar
AuthorShaik, Riyazuddin Mohammad
AuthorAbdul Rahim, Hanan F
AuthorNasrallah, Gheyath K
AuthorAl Kuwari, Mohamed Ghaith
AuthorButt, Adeel A
AuthorAl Romaihi, Hamad Eid
AuthorAl-Thani, Mohamed H
AuthorAl Khal, Abdullatif
AuthorBertollini, Roberto
Available date2022-01-10T07:35:25Z
Publication Date2021-10-17
Publication NameClinical Infectious Diseases
Identifierhttp://dx.doi.org/10.1093/cid/ciab909
URIhttp://hdl.handle.net/10576/25635
AbstractBeta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.
Languageen
PublisherOxford Academic
SubjectSARS-CoV-2
case-control
epidemiology
infection
severe disease
variant
TitleSeverity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
TypeArticle
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record